Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Boulware

Internal Medicine Florence, SC Medical Doctor

NPI 1518930940 CMS profile 68850

501 S Coit St, Florence, SC 29501

Open in the dashboard

General payments

$3,814

225 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Boulware of Florence, SC is reported in the CMS Open Payments database as having received $3,814 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $712 36
2024 General $768 41
2023 General $556 27
2022 General $402 26
2021 General $772 51
2020 General $247 20
2019 General $358 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Boulware
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to William Boulware were reported at $712. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year William Boulware Internal Medicine median Middle half National median
2019 $358 $159 $48–$570 $163
2020 $247 $119 $33–$402 $114
2021 $772 $135 $37–$521 $132
2022 $402 $141 $42–$496 $149
2023 $556 $149 $45–$519 $160
2024 $768 $154 $47–$537 $164
2025 $712 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $784 37 payments
  2. Amgen Inc. $393 27 payments
  3. Merck Sharp & Dohme Corporation $237 12 payments
  4. AbbVie, Inc. $228 17 payments
  5. Sumitomo Pharma America, Inc. $219 9 payments
  6. Esperion Therapeutics, Inc. $187 11 payments
  7. Abbott Laboratories $171 11 payments
  8. Novartis Pharmaceuticals Corporation $161 10 payments
  9. Amarin Pharma Inc. $158 11 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $144 9 payments
  11. Other $1,131 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,814 225 payments
Products named General payments · program years 2019–2025
  1. Ozempic $439 27 payments
  2. RYBELSUS $418 25 payments
  3. GEMTESA $237 10 payments
  4. Prolia $209 14 payments
  5. Repatha $207 14 payments
  6. NEXLETOL $187 11 payments
  7. EVENITY $172 12 payments
  8. Vascepa $158 11 payments
  9. ENTRESTO $142 9 payments
  10. VERQUVO $135 4 payments
  11. Other $2,935 190 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 225 drugs

Part D claims

12,987

Median for Internal Medicine: 777

Drug cost

$1,058,517

Median for Internal Medicine: $73,373

Branded share of claims

23.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 240 $172,341
Jardiance Empagliflozin Brand 119 $86,376
Ozempic Semaglutide Brand 64 $75,493
Rybelsus Semaglutide Brand 69 $67,192
Xarelto Rivaroxaban Brand 82 $57,234
Entresto Sacubitril/Valsartan Brand 38 $32,425
Wellbutrin Xl Bupropion Hcl Brand 12 $31,127
Myrbetriq Mirabegron Brand 43 $27,668
Linzess Linaclotide Brand 34 $25,976
Glyxambi Empagliflozin/Linagliptin Brand 22 $24,722

The 10 drugs with the highest cost, of 225 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$179,258

Of which drugs: $487

Medicare patients

425

Average age 77

Services billed

4,730

246 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 70%
Diabetes 31%
Ischemic heart disease 23%
Chronic kidney disease 23%
Depression 23%
Atrial fibrillation 22%
Cancer 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 24 1,248 $127
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 23 71 $58

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NEXLETOL
  • Esperion Therapeutics, Inc. $102
$102 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $97
$97 — —
RYBELSUS
  • Novo Nordisk Inc $34
$34 69 —
Ozempic
  • Novo Nordisk Inc $34
$34 64 —
UBRELVY
  • AbbVie, Inc. $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record